Brianne Kingery is an associate in the San Diego office. Brianne assists clients in patent prosecution, both in the United States and in over 20 jurisdictions worldwide. Brianne helps advise clients with patentability and freedom-to-operate investigations and analyses, and with IP transactional agreements. Brianne also assists clients in litigation matters, including litigation involving Abbreviated New Drug Applications under the Hatch-Waxman Act and litigation involving trade secrets. Her clients include companies in the biotechnology, biosimilar, pharmaceutical, medical device, and nutraceutical spaces, ranging from startups to established companies. Brianne also assists clients in obtaining design patent protection related to fashion and to personal care products.
Brianne received her J.D. magna cum laude from BYU J. Reuben Clark Law School in 2021. During law school, Brie served as president of the local chapter of the Student Intellectual Property Law Association, as a senior editor on the law review, and as a teaching assistant to an undergraduate Genomics class. She also placed first in the local Giles S. Rich Intellectual Property Moot Court competition. Brie earned her B.S. magna cum laude in Molecular Biology from Brigham Young University in 2018. During her free time, Brie enjoys spending time at the beach, reading, and hiking.
Brianne is fluent in Spanish and Italian. She joined the firm in 2021.
Extern Experience:
Chief Justice Matthew B. Durrant, Utah Supreme Court (Jan – April 2020)
Litigation Blog
- IPR Decision Based on a Barely Mentioned Typo Violated the APA Notice Requirement
- Expert Testimony Inconsistent With Agreed-Upon Claim Construction Is Properly Stricken
- The Patent Office Need Not Consider Requests for Director Review of IPR Institution Decisions
- Claim Limitation Not Disclosed by Any Reference but Disclosed by “Proposed Combination” of References Is Obvious
Biotechnology Blog
-
Allergan v. MSN Laboratories: Federal Circuit Places Limits on Obviousness-Type Double Patenting
-
Medicare Drug Price Negotiation Program Steadily Progressing Despite Lawsuits
-
District Court Finds Mylan (Viatris) Infringes Regeneron’s Eylea Patent
-
Federal Circuit Says Extrinsic Evidence Should Have Been Considered in Claim Construction
-
Merck Sues Federal Government Over Medicare Drug Price Negotiation Program